SELLAS Life Sciences Group Advances Cancer Therapy with GTB-3650 in Phase 1 Trials

GT Biopharma Advances Cancer Treatment with GTB-3650 in Phase 1 Trials

GT Biopharma, Inc. is making significant headway in its Phase 1 clinical trial of GTB-3650, a novel drug designed to treat relapsed or refractory blood cancers such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Recently, the company completed a safety review for the third cohort of its trial, finding no safety or tolerability issues among the six patients treated thus far. This milestone allows GT Biopharma to progress to the fourth cohort, where patients will receive a dose of 10μg/kg/day. With patient screening underway and dosing expected to commence shortly, the company is poised to explore the potential of GTB-3650 in a challenging patient population that has either not responded to existing therapies or has experienced disease recurrence.

The innovative mechanism of GTB-3650 lies in its ability to enhance the body’s natural killer (NK) cells, which play a crucial role in identifying and eliminating cancer cells. The treatment regimen consists of continuous infusions over a two-week period, followed by a two-week rest, and may be repeated for up to four months depending on patient responses. The current trial data has shown promising trends in immunological biomarkers, which the company interprets as indicative of potential clinical efficacy as it moves forward into the next dosing group. As GT Biopharma continues to refine its therapeutic approach, the implications for patients suffering from aggressive blood cancers are significant, offering hope where traditional treatments have fallen short.

GT Biopharma's efforts come at a pivotal moment in the oncology landscape, particularly with the recent approval of the first once-daily menin inhibitor for relapsed NPM1-mutated AML. This approval signifies a growing recognition of targeted therapies in treating blood cancers, underscoring the urgent need for innovative solutions in this arena. As GT Biopharma prepares for its next comprehensive update in the first quarter of 2026, the company remains focused on addressing some of the most difficult cancer challenges through its cutting-edge immunotherapy solutions.

In addition to its ongoing trials, GT Biopharma's advancements highlight the broader trend within the biopharmaceutical industry toward personalized medicine and targeted therapies. The momentum generated by such innovations is crucial for both patient outcomes and the overall evolution of cancer treatment paradigms. As the company continues its clinical journey, the implications of its findings may extend well beyond its own portfolio, influencing future research and development in cancer immunotherapy.